Rapport Therapeutics, Inc. RAPP Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rapport Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rapport Therapeutics, Inc.'s cash & equivalents?
- Rapport Therapeutics, Inc. (RAPP) reported cash & equivalents of $78.06M in Q1 2026.
- How has Rapport Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Rapport Therapeutics, Inc.'s cash & equivalents increased by 35.5% year-over-year, from $57.6M to $78.06M.
- What is the long-term trend for Rapport Therapeutics, Inc.'s cash & equivalents?
- Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s cash & equivalents has grown at a -13.4% compound annual growth rate (CAGR), from $70.17M to $52.65M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.